PCV35 THE BUDGET IMPACT ANALYSIS OF AMBRISENTAN IN 2ND LINE TREATMENT OF ADULT PATIENTS WITH IDIOPATHIC, FAMILIAR OR ASSOCIATED WITH CONNECTIVE TISSUE DISEASE PULMONARY HYPERTENSION OF III NYHA STAGE
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72378-6
https://www.valueinhealthjournal.com/article/S1098-3015(11)72378-6/fulltext
Title :
PCV35 THE BUDGET IMPACT ANALYSIS OF AMBRISENTAN IN 2ND LINE TREATMENT OF ADULT PATIENTS WITH IDIOPATHIC, FAMILIAR OR ASSOCIATED WITH CONNECTIVE TISSUE DISEASE PULMONARY HYPERTENSION OF III NYHA STAGE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72378-6&doi=10.1016/S1098-3015(11)72378-6
First page :
A347
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
537